Tau‐PET uptake, most often quantified by 18F‐flortaucipir, has been shown to be elevated in some LBD patients, especially in DLB who may be more likely to bear tau and Aβ neuropathology, although the degree of uptake is typically less than that observed in AD.19, 20. The gene discussed is MAPT; the disease is Lewy body dementia.